Contact: Amanda Jekowsky, firstname.lastname@example.org, 202-731-3069
NEW DEVICE LOWERS BLOOD PRESSURE BY ACTIVATING THE BODY’S REGULATORS
Phase III Results Show Promise for Treating Hypertension Unresponsive to Conventional Therapy
New Orleans, LA − A novel device that works with the body’s natural mechanisms helps patients with severe and uncontrolled hypertension achieve and maintain target blood pressure levels, according to research presented today at the American College of Cardiology’s 60th Annual Scientific Session. ACC.11 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists to further advances in cardiovascular medicine.
The Rheos® System device is implanted just below the collarbone, like a pacemaker, and delivers four to six volts of electricity to the carotid arteries. The pulses mimic a spike in blood pressure that activates a process called carotid baroreflex. This approach, known as baroflex activation therapy, tricks the brain into harnessing a network of sensors throughout the body that cause blood pressure to drop. Blood pressure >140/90 mmHg is termed Stage 1 hypertension, which increases risk of heart and kidney disease, stroke and death.
“People with resistant hypertension – high blood pressure that doesn’t respond to multidrug therapy and lifestyle changes – are a growing group, and they’re in desperate need of additional treatments,” said John D. Bisognano, M.D., Ph.D., professor of medicine in the Cardiology Division of the University of Rochester, Rochester, N.Y. “The drugs available now are good for most people with hypertension, but people with resistant sky-high blood pressure need more, and it is important that we develop treatments for this growing set of people.”
In this multicenter, Phase III study, the device was implanted in 265 patients with resistant hypertension of >160/80 mmHg who were taking at least three blood pressure drugs, including a diuretic. All patients were then randomly assigned to two groups in a 2-to-1 ratio. The number of medications was similar in the two groups but could not be controlled in the study because most patients had blood pressure far above their goals; thus, physicians often changed their medications. Group A’s devices delivered baroflex activation therapy for the study’s full 12-month duration. Group B patients served as the control group for the first half of the study, and at six months their devices were programmed to begin treatment. The target for systolic blood pressure (SBP), the top number, was <140, and patients were seen monthly. If the patients had not reached the target SBP, the device was adjusted on an individual basis to assert more voltage and further reduce blood pressure.
Both groups showed significant reductions in SBP. In Group A, SBP decreased to target levels for 41 percent of patients after six months and 54 percent after 12 months. Group B showed a surprisingly large placebo effect, even though patients and clinicians were blinded to treatment until after the 12-month visit. Twenty-one percent achieved target SBP during the control phase, and 46 percent were in the target range after six months of treatment. Reductions in SBP at 12 months were at least 50 percent of those seen at six months, demonstrating a sustained response.
Diastolic blood pressure also fell in both groups at both time periods. Although the trial did not meet all primary endpoints, the data showed that the therapy significantly reduced blood pressure in patients with resistant hypertension. At 12 months, there was an 88 percent responder rate – a 35 mmHg blood pressure drop and a decrease in left ventricular mass (the left ventricle enlarges when factors such as hypertension force it to work harder). Future trials need to incorporate measures to improve variability in blood pressure in subjects.
“This system is safe, and its effect is as good as two or three drugs for people who are already taking five or six drugs and still can’t control their hypertension,” Bisognano said. “It’s a good additional option for these patients.”
The study was sponsored by CVRx, Inc., which developed the Rheos® System. Bisognano is a consultant for CVRx, Inc. and has received consulting fees and research support from the company.
Dr. Bisognano will be available to the media on Tuesday, April 5, at 12:30 p.m. CDT, in Room 338/339.
Dr. Bisognano will present the study, “Baroflex Activation Therapy Sustainably Lowers Blood Pressure in Patients with Resistant Hypertension: Results from the Rheos Pivotal Trial,” on Tuesday, April 5, at 10:45 a.m. CDT, in the Joint Main Tent: La Nouvelle.
The American College of Cardiology (www.cardiosource.org) represents the majority of board-certified cardiovascular care professionals through education, research, promotion, development and application of standards and guidelines – and to influence health care policy. ACC.11 is the largest cardiovascular meeting, bringing together cardiologists and cardiovascular specialists to share the newest discoveries in treatment and prevention, while helping the ACC achieve its mission to address and improve issues in cardiovascular medicine.